IVIG regulates BAFF expression in patients with chronic inflammatory demyelinating polyneuropathy (CIDP)

Journal of Neuroimmunology

Volumn 274, Issue 1-2, 2014, Pages 225-229

  Ritter, Christian ^a,c   Förster, Dominik ^b   Albrecht, Philipp ^b   Hartung, Hans Peter ^b   Kieseier, Bernd C ^b   Lehmann, Helmar C ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c FORSCHUNGSZENTRUM JÜLICH   (Germany)

Author keywords

B cell activating factor; CIDP; Cytokine; Immune neuropathy; Therapy; Treatment

Indexed keywords

B CELL ACTIVATING FACTOR RECEPTOR; IMMUNOGLOBULIN;

ADULT; AGED; ARTICLE; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DRUG MEGADOSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FACIAL NERVE PARALYSIS; FEMALE; FLOW CYTOMETRY; HUMAN; HYDROCEPHALUS; MAINTENANCE THERAPY; MALE; MILD COGNITIVE IMPAIRMENT; MULTIPLE SCLEROSIS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADICULOPATHY; SUBARACHNOID HEMORRHAGE; TREATMENT DURATION;

B-CELL ACTIVATING FACTOR; CIDP; CYTOKINE; IMMUNE NEUROPATHY; THERAPY; TREATMENT;

AGED; AGED, 80 AND OVER; AUTOANTIBODIES; B-CELL ACTIVATING FACTOR; DRUG MONITORING; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MALE; MIDDLE AGED; POLYRADICULONEUROPATHY, CHRONIC INFLAMMATORY DEMYELINATING; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 13;

EID: 84908686951     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2014.06.007     Document Type: Article

References (47)

1. Baek A., Park H.J., Na S.J., Shim D.S., Moon J.S., Yang Y., Choi Y.C. The expression of BAFF in the muscles of patients with dermatomyositis. J. Neuroimmunol. 2012, 249:96-100.
2. Bick S., Tschernatsch M., Karg A., Fuehlhuber V., Trenczek T.E., Faltermeier K., Hackstein H., Kaps M., Blaes F. Intravenous immunoglobulin inhibits BAFF production in chronic inflammatory demyelinating polyneuropathy - a new mechanism of action?. J. Neuroimmunol. 2013, 256:84-90.
3. Buttmann M., Kaveri S., Hartung H.P. Polyclonal immunoglobulin G for autoimmune demyelinating nervous system disorders. Trends Pharmacol. Sci. 2013, 34:445-457.
4. Cheema G.S., Roschke V., Hilbert D.M., Stohl W. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum. 2001, 44:1313-1319.
5. Creange A., Gregson N.A., Hughes R.A. Intravenous immunoglobulin modulates lymphocyte CD54 and monocyte FcgammaRII expression in patients with chronic inflammatory neuropathies. J. Neuroimmunol. 2003, 135:91-95.
6. Dalakas M.C. B cells as therapeutic targets in autoimmune neurological disorders. Nat. Clin. Pract. Neurol. 2008, 4:557-567.
7. Dalakas M.C. Advances in the diagnosis, pathogenesis and treatment of CIDP. Nat. Rev. Neurol. 2011, 7:507-517.
8. Eftimov F., Winer J.B., Vermeulen M., de Haan R., van Schaik I.N. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst. Rev. 2013, 12. (CD001797).
9. Fuhlhuber V., Bick S., Kirsten A., Hahn A., Gerriets T., Tschernatsch M., Kaps M., Preissner K.T., Blaes F., Altenkamper S. Elevated B-cell activating factor BAFF, but not APRIL, correlates with CSF cerebellar autoantibodies in pediatric opsoclonus-myoclonus syndrome. J. Neuroimmunol. 2009, 210:87-91.
10. Groom J., Kalled S.L., Cutler A.H., Olson C., Woodcock S.A., Schneider P., Tschopp J., Cachero T.G., Batten M., Wheway J., Mauri D., Cavill D., Gordon T.P., Mackay C.R., Mackay F. Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjogren's syndrome. J. Clin. Invest. 2002, 109:59-68.
11. Hartung H.P. Advances in the understanding of the mechanism of action of IVIg. J. Neurol. 2008, 255(Suppl. 3):3-6.
12. Hughes R.A. Chronic inflammatory demyelinating polyradiculoneuropathy. Ann. Neurol. 2001, 50:281-282.
13. Hughes R.A., Donofrio P., Bril V., Dalakas M.C., Deng C., Hanna K., Hartung H.P., Latov N., Merkies I.S., van Doorn P.A. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol. 2008, 7:136-144.
14. Kaveri S.V. Intravenous immunoglobulin: exploiting the potential of natural antibodies. Autoimmun. Rev. 2012, 11:792-794.
15. Kieseier B.C., Lehmann H.C., Meyer Zu Horste G. Autoimmune diseases of the peripheral nervous system. Autoimmun. Rev. 2012, 11:191-195.
16. Kim J.Y., Yang Y., Moon J.S., Lee E.Y., So S.H., Lee H.S., Park K.D., Choi Y.C. Serum BAFF expression in patients with myasthenia gravis. J. Neuroimmunol. 2008, 199:151-154.
17. Koller H., Kieseier B.C., Jander S., Hartung H.P. Chronic inflammatory demyelinating polyneuropathy. N. Engl. J. Med. 2005, 352:1343-1356.
18. Krystufkova O., Vallerskog T., Helmers S.B., Mann H., Putova I., Belacek J., Malmstrom V., Trollmo C., Vencovsky J., Lundberg I.E. Increased serum levels of B cell activating factor (BAFF) in subsets of patients with idiopathic inflammatory myopathies. Ann. Rheum. Dis. 2009, 68:836-843.
19. Le Pottier L., Bendaoud B., Dueymes M., Daridon C., Youinou P., Shoenfeld Y., Pers J.O. BAFF, a new target for intravenous immunoglobulin in autoimmunity and cancer. J. Clin. Immunol. 2007, 27:257-265.
20. Leandro M.J., Cambridge G. Expression of B cell activating factor (BAFF) and BAFF-binding receptors in rheumatoid arthritis. J. Rheumatol. 2013, 40:1247-1250.
21. Lehmann H.C., Hartung H.P. Plasma exchange and intravenous immunoglobulins: mechanism of action in immune-mediated neuropathies. J. Neuroimmunol. 2011, 231:61-69.
22. Lehmann H.C., Hughes R.A., Hartung H.P. Treatment of chronic inflammatory demyelinating polyradiculoneuropathy. Handb. Clin. Neurol. 2013, 115:415-427.
23. Lewis R.A. Chronic inflammatory demyelinating polyneuropathy and other immune-mediated demyelinating neuropathies. Semin. Neurol. 2005, 25:217-228.
24. Ling Z.D., Yeoh E., Webb B.T., Farrell K., Doucette J., Matheson D.S. Intravenous immunoglobulin induces interferon-gamma and interleukin-6 in vivo. J. Clin. Immunol. 1993, 13:302-309.
25. Mackay F., Leung H. The role of the BAFF/APRIL system on T cell function. Semin. Immunol. 2006, 18:284-289.
26. Mackay F., Woodcock S.A., Lawton P., Ambrose C., Baetscher M., Schneider P., Tschopp J., Browning J.L. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J. Exp. Med. 1999, 190:1697-1710.
27. Mata S., Borsini W., Caldini A., De Scisciolo G., Piacentini S., Taiuti R. Long-term evolution of anti-ganglioside antibody levels in patient with chronic dysimmune neuropathy under IVIg therapy. J. Neuroimmunol. 2006, 181:141-144.
28. Moore P.A., Belvedere O., Orr A., Pieri K., LaFleur D.W., Feng P., Soppet D., Charters M., Gentz R., Parmelee D., Li Y., Galperina O., Giri J., Roschke V., Nardelli B., Carrell J., Sosnovtseva S., Greenfield W., Ruben S.M., Olsen H.S., Fikes J., Hilbert D.M. BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science 1999, 285:260-263.
29. Nardelli B., Belvedere O., Roschke V., Moore P.A., Olsen H.S., Migone T.S., Sosnovtseva S., Carrell J.A., Feng P., Giri J.G., Hilbert D.M. Synthesis and release of B-lymphocyte stimulator from myeloid cells. Blood 2001, 97:198-204.
30. Ng L.G., Sutherland A.P., Newton R., Qian F., Cachero T.G., Scott M.L., Thompson J.S., Wheway J., Chtanova T., Groom J., Sutton I.J., Xin C., Tangye S.G., Kalled S.L., Mackay F., Mackay C.R. B cell-activating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells. J. Immunol. 2004, 173:807-817.
31. Nimmerjahn F., Ravetch J.V. Anti-inflammatory actions of intravenous immunoglobulin. Annu. Rev. Immunol. 2008, 26:513-533.
32. Nobile-Orazio E., Gallia F., Tuccillo F., Terenghi F. Chronic inflammatory demyelinating polyradiculoneuropathy and multifocal motor neuropathy: treatment update. Curr. Opin. Neurol. 2010, 23:519-523.
33. Pers J.O., Daridon C., Devauchelle V., Jousse S., Saraux A., Jamin C., Youinou P. BAFF overexpression is associated with autoantibody production in autoimmune diseases. Ann. N. Y. Acad. Sci. 2005, 1050:34-39.
34. PNS J.T.F.o.t.E.a.t. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. J. Peripher. Nerv. Syst. 2005, 10:220-228.
35. Reinhold D., Perlov E., Schrecke K., Kekow J., Brune T., Sailer M. Increased blood plasma concentrations of TGF-beta isoforms after treatment with intravenous immunoglobulins (i.v.IG) in patients with multiple sclerosis. J. Neuroimmunol. 2004, 152:191-194.
36. Rissmann A., Pieper S., Adams I., Brune T., Wiemann D., Reinhold D. Increased blood plasma concentrations of TGF-beta1 and TGF-beta2 after treatment with intravenous immunoglobulins in childhood autoimmune diseases. Pediatr. Allergy Immunol. 2009, 20:261-265.
37. Schneider P., MacKay F., Steiner V., Hofmann K., Bodmer J.L., Holler N., Ambrose C., Lawton P., Bixler S., Acha-Orbea H., Valmori D., Romero P., Werner-Favre C., Zubler R.H., Browning J.L., Tschopp J. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J. Exp. Med. 1999, 189:1747-1756.
38. Sewell W.A., North M.E., Cambronero R., Webster A.D., Farrant J. In vivo modulation of cytokine synthesis by intravenous immunoglobulin. Clin. Exp. Immunol. 1999, 116:509-515.
39. Thangarajh M., Masterman T., Helgeland L., Rot U., Jonsson M.V., Eide G.E., Pirskanen R., Hillert J., Jonsson R. The thymus is a source of B-cell-survival factors - APRIL and BAFF - in myasthenia gravis. J. Neuroimmunol. 2006, 178:161-166.
40. Thien M., Phan T.G., Gardam S., Amesbury M., Basten A., Mackay F., Brink R. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity 2004, 20:785-798.
41. Vallat J.M., Sommer C., Magy L. Chronic inflammatory demyelinating polyradiculoneuropathy: diagnostic and therapeutic challenges for a treatable condition. Lancet Neurol. 2010, 9:402-412.
42. Vani J., Elluru S., Negi V.S., Lacroix-Desmazes S., Kazatchkine M.D., Bayry J., Kaveri S.V. Role of natural antibodies in immune homeostasis: IVIg perspective. Autoimmun. Rev. 2008, 7:440-444.
43. Vincent F.B., Morand E.F., Mackay F. BAFF and innate immunity: new therapeutic targets for systemic lupus erythematosus. Immunol. Cell Biol. 2011, 90:293-303.
44. Vincent F.B., Morand E.F., Mackay F. BAFF and innate immunity: new therapeutic targets for systemic lupus erythematosus. Immunol. Cell Biol. 2012, 90:293-303.
45. Vincent F.B., Saulep-Easton D., Figgett W.A., Fairfax K.A., Mackay F. The BAFF/APRIL system: emerging functions beyond B cell biology and autoimmunity. Cytokine Growth Factor Rev. 2013, 24:203-215.
46. Yoshimoto K., Takahashi Y., Ogasawara M., Setoyama Y., Suzuki K., Tsuzaka K., Abe T., Takeuchi T. Aberrant expression of BAFF in T cells of systemic lupus erythematosus, which is recapitulated by a human T cell line, Loucy. Int. Immunol. 2006, 18:1189-1196.
47. Zhang J., Roschke V., Baker K.P., Wang Z., Alarcon G.S., Fessler B.J., Bastian H., Kimberly R.P., Zhou T. Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J. Immunol. 2001, 166:6-10.